💨 Abstract

A new study published in The Lancet Neurology reveals that an experimental drug reduces the risk of Alzheimer's-related dementia in individuals with genetic mutations causing early-onset disease. The drug, which targets amyloid plaques in the brain, delayed the onset of symptoms by half for a subgroup of participants who received the treatment for eight years and had no cognitive problems at the study's start.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖